Literature DB >> 6601041

BT-PABA test with plasma PABA measurements: evaluation of sensitivity and specificity.

J C Delchier, J C Soule.   

Abstract

Urinary recovery and plasma time curve of PABA were determined in 15 control subjects and 65 patients during a six hour period after ingestion of a meal containing 1 g BT-PABA (2.333 mmol PABA). In controls, the plasma PABA time curve registered a peak at two hours followed by a rapid decrease to reach its lowest value at six hours. In patients with chronic pancreatitis (n=32), the peak was lower and was followed by a slow decrease; furthermore, it was delayed in those with severe pancreatic insufficiency. The best discrimination between controls and patients with chronic pancreatitis was obtained by using the maximal value of plasma PABA (MPPABA) at two or three hours. In 56 subjects a hyperbolic relationship between MPPABA and duodenal lipase output stimulated by a meal was mathematically demonstrated and it was calculated that the lower limit of normal MPPABA (mean -2 SD) corresponded to a lipase output equal to 20.6% of the mean value of normal subjects (lower limit of normal lipase output = 40%). By comparison, steatorrhoea occurred when lipase output was less than 10%. Consequently, MPPABA was low not only in all patients with steatorrhoea but also in some who had pancreatic deficiency but normal daily faecal fat. With lipase output as the reference, 12 subjects who had normal MPPABA were proved to have falsely abnormal urinary results. Urinary PABA excretion after oral administration of 2.333 mmol free PABA was also determined in 27 subjects. The PABA excretion index (PEI) was calculated: PEI = PABA urinary excretion after BT-PABA/PABA urinary excretion after free PABA. Seven patients with normal MPPABA but low urinary excretion after BT-PABA had a normal PABA excretion index. It was also observed that, in five patients with intestinal disease, free PABA absorption was not impaired. In conclusion, BTPABA test with MPPABA determination used as an index of exocrine function is (1) less sensitive than Lundh's test, but more sensitive than steatorrhoea; (2) more specific than the test with urinary recovery determination alone, and as specific as PABA excretion index, which requires a double test.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6601041      PMCID: PMC1419965          DOI: 10.1136/gut.24.4.318

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  17 in total

1.  Pancreatic secretion of total protein and of three hydrolases collected in healthy subjects via duodenoscopic cannulation. Effects of secretin, pancreozymin, and caerulein.

Authors:  P Robberecht; M Cremer; A Vandermeers; M C Vandermeers-Piret; P Cotton; P De Neef; J Christophe
Journal:  Gastroenterology       Date:  1975-08       Impact factor: 22.682

2.  Diagnosis of exocrine pancreatic insufficiency in cystic fibrosis by the synthetic peptide N-benzoyl-L-tyrosyl-p-aminobenzoic acid.

Authors:  S Nousia-Arvanitakis; C Arvanitakis; N Desai; N J Greenberger
Journal:  J Pediatr       Date:  1978-05       Impact factor: 4.406

3.  [Indirect assessment of exocrine pancreatic function by oral administration of a synthetic peptide, N-benzoyl-L-tyrosyl-para-amino-benzoic-acid (PABA test) (author's transl)].

Authors:  A Ribet; J Frexinos; J Escourrou; N Vaysse; Y Arany; M Varignon
Journal:  Gastroenterol Clin Biol       Date:  1979-03

4.  In vitro and in vivo analysis of the PABA test compared with the Lundh test--influence of intraluminal pH.

Authors:  F J Hoek; G T Sanders; A Teunen; G N Tijtgat
Journal:  Gut       Date:  1981-01       Impact factor: 23.059

5.  [Study of pure human pancreatic juice collected after secretion and caerulein stimulation (author's transl)].

Authors:  J Escourrou; J Frexinos; A Ribet
Journal:  Gastroenterol Clin Biol       Date:  1978-01

6.  Diagnosis of pancreatic disease by a synthetic peptide. A new test of exocrine pancreatic function.

Authors:  C Arvanitakis; N J Greenberger
Journal:  Lancet       Date:  1976-03-27       Impact factor: 79.321

7.  Oral administration of a chymotrypsin-labile peptide--a new test of exocrine pancreatic function in man (PFT).

Authors:  K Gyr; G A Stalder; I Schiffmann; C Fehr; D Vonderschmitt; H Fahrlaender
Journal:  Gut       Date:  1976-01       Impact factor: 23.059

8.  The diagnostic value of the oral pancreatic function test.

Authors:  C J Mitchell; C S Humphrey; A W Bullen; J Kelleher
Journal:  Scand J Gastroenterol       Date:  1979       Impact factor: 2.423

9.  Improved diagnostic accuracy of a modified oral pancreatic function test.

Authors:  C J Mitchell; C S Humphrey; A W Bullen; J Kelleher; M S Losowsky
Journal:  Scand J Gastroenterol       Date:  1979       Impact factor: 2.423

10.  A test of pancreatic function in man based on the analysis of duodenal contents after administration of secretin and pancreozymin.

Authors:  P BURTON; D G EVANS; A A HARPER; T HOWATH; S OLEESKY; J E SCOTT; H VARLEY
Journal:  Gut       Date:  1960-06       Impact factor: 23.059

View more
  11 in total

1.  Comparison of BT-PABA test and fecal chymotrypsin measurements in normal subjects and diabetic patients.

Authors:  G Montalto; A Carroccio; G Marino; M Soresi; C Di Marco; A Notarbartolo
Journal:  Acta Diabetol Lat       Date:  1990 Apr-Jun

2.  Pancreatic function testing: serum PABA measurement is a reliable and accurate measurement of exocrine function.

Authors:  A R Tanner; D P Robinson
Journal:  Gut       Date:  1988-12       Impact factor: 23.059

Review 3.  Function tests in the diagnosis of chronic pancreatitis. Critical evaluation.

Authors:  P G Lankisch
Journal:  Int J Pancreatol       Date:  1993-08

4.  Value of serum PABA as a pancreatic function test.

Authors:  C Lang; K Gyr; I Tonko; D Conen; G A Stalder
Journal:  Gut       Date:  1984-05       Impact factor: 23.059

5.  Comparison of the oral (PABA) pancreatic function test, the secretin-pancreozymin test and endoscopic retrograde pancreatography in chronic alcohol induced pancreatitis.

Authors:  A S Mee; A H Girdwood; E Walker; N H Gilinsky; R E Kottler; I N Marks
Journal:  Gut       Date:  1985-11       Impact factor: 23.059

6.  Serum PABA and fluorescein in the course of Bz-Ty-PABA and pancreolauryl test as an index of exocrine pancreatic insufficiency.

Authors:  G Cavallini; W Piubello; G Brocco; R Micciolo; G Chech; G Angelini; L Benini; A Riela; L Dalle Molle; I Vantini
Journal:  Dig Dis Sci       Date:  1985-07       Impact factor: 3.199

7.  Altered PABA pharmacokinetics in cystic fibrosis. Implications for bentiromide test.

Authors:  G Koren; Z Weizman; G Forstner; S M MacLeod; P R Durie
Journal:  Dig Dis Sci       Date:  1985-10       Impact factor: 3.199

8.  The usefulness of serum PABA measurement after BT-PABA administration in the diagnosis of chronic pancreatitis.

Authors:  R Myoen; T Takebe; K Ohyama
Journal:  Gastroenterol Jpn       Date:  1985-10

9.  BT-Paba test in the diagnosis of pancreatic exocrine insufficiency in cystic fibrosis: urinary and serum determinations compared.

Authors:  S Bellentani; A Grisendi; M Rinaldi; P Bertolani; G Costa; M Agostini; G Mastella; F Balli; F Manenti
Journal:  Eur J Pediatr       Date:  1984-12       Impact factor: 3.183

10.  The development of the chymotryptic activity during postnatal life using the bentiromide test.

Authors:  Y Bujanover; A Harel; R Geter; H Blau; J Yahav; Z Spirer
Journal:  Int J Pancreatol       Date:  1988 Jan-Feb
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.